|
original article |
Journal |
Date |
Title |
Authors All Authors |
1 |
[GO] |
Drugs in Context |
2023―Jun―26 |
Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data |
Christoph Lübbert, Igor Dykukha, Jann-Patrick Pelz, Helen Yearley, Wolfgang Junker, Nina Gruber, et al. (+4) Sibyll Escher, Katrin Biereth, Sima Melnik, Julia Puschmann |
2 |
[GO] |
Drugs in Context |
2023―Jun―07 |
Changes in nasal, pharyngeal and salivary secretory IgA levels in patients with COVID-19 and the possibility of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms |
Mikhail Kostinov, Oksana Svitich, Alexander Chuchalin, Natalya Abramova, Valery Osiptsov, Ekaterina Khromova, et al. (+8) Dmitry Pakhomov, Vitaly Tatevosov, Anna Vlasenko, Vilia Gainitdinova, Kirill Mashilov, Nadezhda Kryukova, Irina Baranova, Anton Kostinov |
3 |
[GO] |
Drugs in Context |
2023―Feb―15 |
A single-centre experience rolling out an antibiotic stewardship intervention prior to and during the SARS-CoV-2 pandemic 2019-2022 |
Zahra Kassamali Escobar, Todd Bouchard, Cameron Buck, Kamaldeep Sandhu, Chloe Bryson-Cahn |
4 |
[GO] |
Drugs in Context |
2023―Feb―06 |
COVID-19 therapy and vaccination: a clinical narrative review |
Siddharth Chinta, Miguel Rodriguez-Guerra, Mohammed Shaban, Neelanjana Pandey, Maria Jaquez-Duran, Timothy J Vittorio |
5 |
[GO] |
Drugs in Context |
2022―Jun―16 |
Addressing COVID-19 vaccine hesitancy |
George Kassianos, Joan Puig-Barberà, Hannah Dinse, Martin Teufel, Özlem Türeci, Shanti Pather |
6 |
[GO] |
Drugs in Context |
2022―Apr―08 |
Real-world use of inhaled nitric oxide therapy in patients with COVID-19 and mild-to-moderate acute respiratory distress syndrome |
Steven H Abman, Nicholas R Fox, M Ibrahim Malik, Sneha S Kelkar, Shelby L Corman, Sanika Rege, et al. (+7) Jenna Bhaloo, Rachel Shah, Ren-Jay Shei, Dana Saporito, Nisreen Shamseddine, Erik DeBoer, George J Wan |
7 |
[GO] |
Drugs in Context |
2022―Mar―01 |
Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19 |
Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Luydmila Yu Akhieva, Elena V Kuntsevich, Anastasia A Troshina, et al. (+6) Elena I Kvasova, Anton A Tikhonov, Nadezhda F Khomyakova, Francisco Harrison, Jean-François Rossi, Timothy C Hardman |
8 |
[GO] |
Drugs in Context |
2022―Jan―21 |
Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL* protocol |
Juan José Cerezo-Manchado, Olga Meca Birlanga, Luis García de Guadiana Romualdo, Ignacio Gil-Ortega, Antonio Martínez Francés, Teodoro Iturbe-Hernandez |
9 |
[GO] |
Drugs in Context |
2021―Dec―12 |
COVID-19-related adaptations to the implementation and evaluation of a clinic-based intervention designed to improve opioid safety |
Anna R Morgan, Michelle A Hendricks, Sanae El Ibrahimi, Sara E Hallvik, Brigit Hatch, Caitlin Dickinson, et al. (+2) Dagan Wright, Michael A Fischer |
10 |
[GO] |
Drugs in Context |
2021―Oct―05 |
Vitamins, supplements and COVID-19: a review of currently available evidence |
Lauren Speakman, Sarah Michienzi, Melissa Badowski |
11 |
[GO] |
Drugs in Context |
2021―Jun―23 |
Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study |
Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, et al. (+5) Yulia S Karpova, Anton Tikhonov, Nadezhda F Khomyakova, Tim Hardman, Jean-François Rossi |
12 |
[GO] |
Drugs in Context |
2021―Jun―08 |
Dermatologists’ attitude towards psoriasis treatment during the COVID-19 pandemic |
Tiago Torres, Marta Pereira, Maria João Paiva Lopes, Clarisse Rebelo, Pedro Andrade, Martinha Henrique, et al. (+7) Hugo Oliveira, Paulo Ferreira, Gabriela Marques Pinto, Francisco Menezes Brandão, Jorge Rozeira, Paulo Filipe, Rui Tavares Bello |
13 |
[GO] |
Drugs in Context |
2021―May―24 |
The UK approach to COVID-19 vaccination: why was it so different? |
Peter MB English |
14 |
[GO] |
Drugs in Context |
2021―Mar―23 |
The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study |
Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, et al. (+5) Yulia S Karpova, Anton Tikhonov, Nadezhda F Khomyakova, Tim Hardman, Jean-François Rossi |
15 |
[GO] |
Drugs in Context |
2021―Feb―15 |
The race to a COVID-19 vaccine: opportunities and challenges in development and distribution |
Rodrigo M Burgos, Melissa E Badowski, Emily Drwiega, Samaneh Ghassemi, Nikki Griffith, Fischer Herald, et al. (+3) Mikayla Johnson, Renata O Smith, Sarah M Michienzi |
16 |
[GO] |
Drugs in Context |
2021―Jan―29 |
Current treatment in COVID-19 disease: a rapid review |
Miguel Rodriguez-Guerra, Preeti Jadhav, Timothy J Vittorio |
17 |
[GO] |
Drugs in Context |
2020―Sep―16 |
Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol |
Teodoro Iturbe-Hernandez, Luis García de Guadiana Romualdo, Ignacio Gil Ortega, Antonio Martínez Francés, Olga Meca Birlanga, Juan José Cerezo-Manchado |
18 |
[GO] |
Drugs in Context |
2020―Jun―29 |
Coronavirus disease 2019 (COVID-19): latest developments in potential treatments |
Kam Lun Hon, Karen Ka Yan Leung, Alexander KC Leung, Su Yun Qian, Vivian PY Chan, Patrick Ip, Ian CK Wong |
19 |
[GO] |
Drugs in Context |
2020―Jun―20 |
Can vitamins and/or supplements provide hope against coronavirus? |
Sarah M Michienzi, Melissa E Badowski |
20 |
[GO] |
Drugs in Context |
2020―Jun―10 |
Neurological features of COVID-19 and their treatment: a review |
Daniele Orsucci, Elena Caldarazzo Ienco, Gianpaolo Nocita, Alessandro Napolitano, Marco Vista |
21 |
[GO] |
Drugs in Context |
2020―May―23 |
A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic |
Matteo Bassetti, Paolo Pelosi, Chiara Robba, Antonio Vena, Daniele Roberto Giacobbe |
22 |
[GO] |
Drugs in Context |
2020―May―20 |
The journey of remdesivir: from Ebola to COVID-19 |
Joe Pardo, Ashutosh M Shukla, Gajapathiraju Chamarthi, Asmita Gupte |
23 |
[GO] |
Drugs in Context |
2020―May―17 |
Pharmacological treatment of COVID-19: lights and shadows |
Francesco Menzella, Mirella Biava, Chiara Barbieri, Francesco Livrieri, Nicola Facciolongo |
24 |
[GO] |
Drugs in Context |
2020―May―13 |
Psoriasis, biologic therapy, and the pandemic of the 21st century |
Miguel Nogueira, Ron Vender, Tiago Torres |
25 |
[GO] |
Drugs in Context |
2020―May―10 |
Facing the COVID-19 outbreak in children with cancer |
Antonio Ruggiero, Alberto Romano, Giorgio Attinà |
26 |
[GO] |
Drugs in Context |
2020―Apr―27 |
Chloroquine and hydroxychloroquine in the context of COVID-19 |
Ashutosh M Shukla, Lennox K Archibald, Aparna Wagle Shukla, Hiren J Mehta, Kartikeya Cherabuddi |